of patient specimens, integration of high throughput screening, and use of molecular heterogeneity in biomarker discovery, we are poised to make progress in ovarian cancer screening. This review will summarize current biomarkers, imaging, and multimodality screening strategies in the context of emerging technologies.
No takes yet. Share an insight, caveat, or question.
Joshua G. Cohen (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: